drugset / Trial / NCT02531737
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether nintedanib (vargatef®) combined with docetaxel are effective in second line of treatment in patients with no squamous non small cell lung cancer refractory to first line chemotherapy.
Timeline
- Start
- 2015-09
- Primary completion
- 2020-09-26
- Completion
- 2020-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nintedanib | Small molecule | 400 mg | Oral |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |